Skip to content

Infants Fed an Amino Acid-based Formula

Symptom Changes in Infants Fed an Amino Acid-based Formula

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04127656
Enrollment
26
Registered
2019-10-15
Start date
2019-12-16
Completion date
2021-12-16
Last updated
2022-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Allergy

Brief summary

To observe the effects of an amino acid-based formula on symptoms associated with food allergies in infants.

Interventions

OTHERAmino Acid-Based Experimental Study Formula

Amino Acid-Based Formula; fed ad libitum

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 12 Months
Healthy volunteers
No

Inclusion criteria

* Subject is judged to be in good health as determined from subject's medical history * Subject is from a full-term birth with a gestational age of 37-42 weeks * Subject's birth weight was ≥ 2490 g (\ 5 lbs. 8 oz.) * Subject has been documented to have CMPA and/or multiple food allergies, FPIES or gastrointestinal eosinophilic disorders. * Subject is experiencing persistent feeding intolerance symptoms including any of the following: regurgitation/vomiting associated with feeding (within 1 hour), constipation, diarrhoea, hematochezia (blood in the stool), crying, gassiness (wind), and/or skin rash/eczema. * Parent(s) confirm their intention to feed their infant study product during the study period. * Parent(s) confirm their intention not to administer vitamin or mineral supplements to their infant from enrolment through the duration of the study, unless instructed otherwise by their healthcare professional. * Infant using medications (OTC medications for gas \[wind\]), home remedies (such as juice for constipation), herbal preparations, prebiotics, probiotics or rehydration fluids that might affect Gl tolerance may not be enrolled unless the parent agrees to discontinue the use of these agents prior to enrolment or a healthcare professional recommends their continued use. * Subject's parent(s) has voluntarily signed and dated an ICF, approved by an IEC/IRB and provided applicable privacy regulation authorisation prior to any participation in the study.

Exclusion criteria

* Subject is receiving steroids or antibiotics * Subject is tube-fed * Subject has received an amino acid-based formula * Subject has been diagnosed with: Short bowel syndrome, Inflammatory bowel disease, Pancreatic disease, Protein maldigestion (malnutrition), Mast cell disorder * Subject is participating in another study that has not been approved as a concomitant study by AN

Design outcomes

Primary

MeasureTime frameDescription
Food Allergy Symptom ImprovementBaseline to Day 28Parent Completed Symptom Diary

Secondary

MeasureTime frameDescription
Time to Symptom Resolution or ReductionBaseline to Day 28Parent Completed Symptom Diary
Change in LengthBaseline to Day 28Length-for-age z scores
Change in WeightBaseline to Day 28Weight-for-age z scores
Study Formula IntakeBaseline to Day 28Parent Completed Intake Diary

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026